Business Context and Reporting Period
This Form 8-K was filed by ChromaDex Corporation on September 15, 2016. The filing reports the entry into a material definitive agreement by ChromaDex, Inc., a wholly owned subsidiary, with Thorne Research, Inc. regarding the supply of the NIAGEN® product (nicotinamide riboside).
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period. The primary financial metric disclosed is a contractual commitment:
- Minimum Purchase Requirement: Approximately $6.0 million from Thorne Research, Inc. for the period October 1, 2016, through December 31, 2018.
Material Changes
The Company executed a Second Addendum to its existing Nicotinamide Riboside Supply Agreement with Thorne Research, Inc. Key changes include:
- Term Extension: The agreement term is extended through December 31, 2018.
- Exclusivity Conditions: Thorne retains exclusivity in specific territories and channels contingent on meeting the $6.0 million minimum purchase requirement.
- Scope of Exclusivity:
- Stand-alone nicotinamide riboside in the licensed healthcare professionals channel in the United States.
- Combinations of nicotinamide riboside with other compounds in all channels in the United States and Canada, with a right of first refusal for other countries.
Guidance, Outlook, and Risks
The filing does not contain forward-looking financial guidance or management commentary regarding future earnings. The primary contingency noted is that Thorne's retention of exclusivity is conditional upon meeting the specified minimum purchase requirements. Additionally, the Company intends to file the full agreement as an exhibit to its Form 10-Q, with certain portions subject to a request for confidential treatment.
Investor Verification Checklist
- Verify the execution of the Second Addendum and the specific terms regarding the $6.0 million minimum purchase obligation.
- Monitor the upcoming Form 10-Q for the quarter ending October 1, 2016, to review the full text of the agreement and the confidential treatment request.
- Assess Thorne Research, Inc.'s ability to meet the purchase milestones required to maintain exclusivity in the U.S. and Canadian markets.